2470 related articles for article (PubMed ID: 29162153)
1. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
2. Neurological toxicities associated with immune-checkpoint inhibitors.
Touat M; Talmasov D; Ricard D; Psimaras D
Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
[TBL] [Abstract][Full Text] [Related]
3. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
4. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
Brahmer JR; Abu-Sbeih H; Ascierto PA; Brufsky J; Cappelli LC; Cortazar FB; Gerber DE; Hamad L; Hansen E; Johnson DB; Lacouture ME; Masters GA; Naidoo J; Nanni M; Perales MA; Puzanov I; Santomasso BD; Shanbhag SP; Sharma R; Skondra D; Sosman JA; Turner M; Ernstoff MS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172516
[TBL] [Abstract][Full Text] [Related]
5. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Naidoo J; Murphy C; Atkins MB; Brahmer JR; Champiat S; Feltquate D; Krug LM; Moslehi J; Pietanza MC; Riemer J; Robert C; Sharon E; Suarez-Almazor ME; Suresh K; Turner M; Weber J; Cappelli LC
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001909
[TBL] [Abstract][Full Text] [Related]
6. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
7. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
8. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
Shannon VR; Anderson R; Blidner A; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson DB; Suarez-Almazor ME; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6145-6157. PubMed ID: 32880733
[TBL] [Abstract][Full Text] [Related]
9. [No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].
Steenbruggen TG; van den Heuvel MM; Blank CU; van Dieren JM; Haanen JB; Kok M
Ned Tijdschr Geneeskd; 2016; 160():A9873. PubMed ID: 27438388
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
[TBL] [Abstract][Full Text] [Related]
11. [The pathology of adverse events with immune checkpoint inhibitors].
Koelzer VH; Glatz K; Bubendorf L; Weber A; Gaspert A; Cathomas G; Lugli A; Zippelius A; Kempf W; Mertz KD
Pathologe; 2017 May; 38(3):197-208. PubMed ID: 28421272
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and Treatment Recommendation and Exploration for Critical and Refractory Adverse Effects Related to Immunocheckpoint Inhibitors].
Wang H; Song P; Si X; Guo X; Li Y; Zhou J; Duan L; Zhang L; Wang M; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):605-614. PubMed ID: 31650941
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
14. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).
Majem M; García-Martínez E; Martinez M; Muñoz-Couselo E; Rodriguez-Abreu D; Alvarez R; Arance A; Berrocal A; de la Cruz-Merino L; Lopez-Martin JA
Clin Transl Oncol; 2020 Feb; 22(2):213-222. PubMed ID: 31993963
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead.
Patil PD; Burotto M; Velcheti V
Expert Rev Mol Diagn; 2018 Mar; 18(3):297-305. PubMed ID: 29430978
[TBL] [Abstract][Full Text] [Related]
16. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.
Chhabra N; Kennedy J
J Med Toxicol; 2021 Oct; 17(4):411-424. PubMed ID: 33826117
[TBL] [Abstract][Full Text] [Related]
17. Testing Immune-Related Adverse Events in Cancer Immunotherapy.
Farmer JR
Clin Lab Med; 2019 Dec; 39(4):669-683. PubMed ID: 31668277
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.
Kottschade LA
Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902
[TBL] [Abstract][Full Text] [Related]
19. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department.
Lipe DN; Shafer S
Clin Toxicol (Phila); 2021 May; 59(5):376-385. PubMed ID: 33576256
[TBL] [Abstract][Full Text] [Related]
20. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]